Descripción:

North Central Cancer Treatment Group N0577 Event Monitoring Form Radiation Therapy or Radiation Therapy and Temozolomide or Temozolomide Alone in Treating Patients With Newly Diagnosed Anaplastic Glioma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=4C090D31-BB06-2FAA-E044-0003BA3F9857

Link:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=4C090D31-BB06-2FAA-E044-0003BA3F9857
Palabras clave:
Versiones (3)
  1. 18/12/14 18/12/14 - Martin Dugas
  2. 8/1/15 8/1/15 - Martin Dugas
  3. 9/1/15 9/1/15 - Martin Dugas
Subido en:

18 de diciembre de 2014

DOI:
Para solicitar uno, por favor iniciar sesión.
Licencia :
Creative Commons BY-NC 3.0 Legacy
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Event Monitoring Form N0577

Inglés
Detalles

No Instruction available.

1 formularios  
  1. StudyEvent: North Central Cancer Treatment Group N0577 Event Monitoring Form
    1. No Instruction available.
Header
Are data amended (If yes, highlight amended areas)
Were you able to obtain any information about the patient since the last report (If this is the first event monitoring form check yes, enter assessment date and complete the rest of the form.)
Vital Status
Vital Status
Primary Cause of Death
Disease Follow-up Status
Has the patient had a documented clinical assessment for this cancer? (since submission of the last event monitoring form)
Notice Of First Relapse/progression In The Event Monitoring Phase
Has the patient developed a first relapse or progression that has not been previously reported
Site of relapse/progression (s)
Method of Evaluation
Notice Of First Subsequent Treatment
Has the patient received subsequent treatment for this cancer that has not been previously reported
Notice Of New Primary
Has a new primary cancer or MDS been diagnosed that has not been previously reported? (myelodyplastic syndrome)
Description Of Primary Disease
Has the patient experienced (prior to treatment for progression or relapse or a second primary, and prior to non-protocol treatment) any severe (grade >=3) long term toxicity that has not been previously reported?
CTC Adverse Event Grade (Highest Grade)
CTC AE Attribution Code
Volver a la parte superior de la página

Similar models

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial